Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, Zhang Z (2009) P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. doi:10.​1007/​s10549-009-0480-4
2.
Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL (1998) p53 polymorphism and risk of cervical cancer. Nature 396:530–531CrossRefPubMed
3.
Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, Husain SA, Das BC (2003) Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252:117–124CrossRefPubMed
4.
Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27CrossRefPubMed
5.
Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42CrossRefPubMed
6.
Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711–714PubMed
7.
Buyru N, Altinisik J, Demokan S, Dalay N (2007) p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207–213CrossRefPubMed
Metadata
Title
Eligible and not eligible studies in the recent meta-analysis about p53 polymorphism and breast cancer risk
Authors
Theodoros N. Sergentanis
Konstantinos P. Economopoulos
Publication date
01-02-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0515-x

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue

Letter to the editor

A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer

Epidemiology

Urban–rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt

Epidemiology

Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province

Preclinical study

A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

Epidemiology

Impact of obesity on diagnosis and treatment of breast cancer

Preclinical study

Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits